text-only page produced automatically by Usablenet Assistive Skip all navigation and go to page content Skip top navigation and go to directorate navigation Skip top navigation and go to page navigation
National Science Foundation
Awards
design element
Search Awards
Recent Awards
Presidential and Honorary Awards
About Awards
Grant Policy Manual
Grant General Conditions
Cooperative Agreement Conditions
Special Conditions
Federal Demonstration Partnership
Policy Office Website



Award Abstract #1346486

STTR Phase I: A noninvasive gene expression based classifier for oral cancer

NSF Org: IIP
Div Of Industrial Innovation & Partnersh
divider line
Initial Amendment Date: December 31, 2013
divider line
Latest Amendment Date: April 21, 2014
divider line
Award Number: 1346486
divider line
Award Instrument: Standard Grant
divider line
Program Manager: Jesus Soriano Molla
IIP Div Of Industrial Innovation & Partnersh
ENG Directorate For Engineering
divider line
Start Date: January 1, 2014
divider line
End Date: December 31, 2014 (Estimated)
divider line
Awarded Amount to Date: $225,000.00
divider line
Investigator(s): Keven Johnson kevenj54@gmail.com (Principal Investigator)
Minakshi Joshi (Former Principal Investigator)
Guy Adami (Co-Principal Investigator)
divider line
Sponsor: ARPHION LTD.
600 N Lake Shore Dr. Apt 3302
Chicago, IL 60611-5086 (312)951-9201
divider line
NSF Program(s): STTR PHASE I
divider line
Program Reference Code(s): 1505, 7236, 7909, 8038, 8042
divider line
Program Element Code(s): 1505

ABSTRACT

This Small Business Technology Transfer Research (STTR) Phase I project will focus on oral cancer (OC), a disease that strikes over 30,000 new patients each year in the US resulting in about 8,000 deaths and even more disfigurements. This costs hundreds of millions of dollars in medical fees. A surgical biopsy with histopathology diagnosis is routine for oral tumor assessment and about one million oral biopsies are done each year in the US. Currently a dentist will detect a discoloration or spot in the patient?s mouth and advise the patient to see an oral surgeon to have the lesion surgically biopsied if it remains 2 weeks later. However, many patients wish to avoid the biopsy, choose to ignore the lesion, and if it is early cancer it goes undetected. There is a clear need for a noninvasive method to detect early OC. The study proposes to use a small brush to obtain cells from oral discolorations that may be early cancers and then analyze the RNA. If done properly this analysis may allow the detection of a developing cancer This provides a means to detect oral cancer early when it can be cured, that does not rely on a surgical biopsy.

The broader impact/commercial potential of this project is to make the detection and diagnosis of early oral cancer one-step, noninvasive, and accurate. This would make the detection of this cancer easier, increase the percentage of oral cancers that are detected early and result in improved cure rates. These patient are treated just with surgery require no chemotherapy or radiation and usually do very well. The goal of this project is create the first non-invasive oral cancer cell based detection kits involving RNA or DNA analysis to be used in the clinic. The technology, gene expression based classification, could be adapted to diagnose other oral diseases often misdiagnosed and inaccurately linked to oral cancer such as lichen planus, papilloma, severe gingivitis, etc.

 

Please report errors in award information by writing to: awardsearch@nsf.gov.

 

 

Print this page
Back to Top of page
  FUNDING   AWARDS   DISCOVERIES   NEWS   PUBLICATIONS   STATISTICS   ABOUT NSF   FASTLANE  
Research.gov  |  USA.gov  |  National Science Board  |  Recovery Act  |  Budget and Performance  |  Annual Financial Report
Web Policies and Important Links  |  Privacy  |  FOIA  |  NO FEAR Act  |  Inspector General  |  Webmaster Contact  |  Site Map
National Science Foundation Logo
The National Science Foundation, 4201 Wilson Boulevard, Arlington, Virginia 22230, USA
Tel: (703) 292-5111, FIRS: (800) 877-8339 | TDD: (800) 281-8749
  Text Only Version